Study guide

Dry eye, blepharitis and meibomian dysfunction

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Dry eye, blepharitis and meibomian dysfunction

Key Takeaways Explain This Topic AI

Current TFOS DEWS III assessment combines symptoms, homeostasis testing and the drivers of disease.

Aqueous, lipid, mucin and lid-related problems require a treatment plan matched to the observed mechanism.

Collarettes support Demodex disease, but targeted therapy and formulation safety depend on clinical context and local availability.

Last updated: October 2026

Dry eye disease (DED) is common in anterior-segment practice and can impair comfort and visual quality. TFOS DEWS III, published in 2025, updates the earlier 2017 consensus. It describes symptomatic, multifactorial loss of tear-film and/or ocular-surface homeostasis, involving instability, hyperosmolarity, inflammation, surface damage and neurosensory factors.

The diagnostic task is to establish symptoms and evidence of lost homeostasis, then identify the contributing drivers. Treating all patients as though they have one identical inflammatory process misses lid, tear, anatomical and sensory abnormalities.

1. Anatomy of the Precorneal Tear Film

Historical models conceptualised the tear film as a distinct trilaminar sandwich (lipid, aqueous, and mucin). Contemporary biophysical research demonstrates that the tear film consists of a superficial lipid layer overlying a blended, continuous muco-aqueous gradient ( 3 – 5 μ m 3–5\,\mu\text{m} 3–5 μ m thickness):

Lipid layer: Meibomian glands provide lipids that contribute to tear-film stability and resistance to evaporation. The effect depends on composition and structure; one universal percentage reduction is not a clinical law.

Muco-Aqueous Layer ( 3 – 5 μ m 3–5\,\mu\text{m} 3–5 μ m ) : Secreted predominantly by the main lacrimal gland and accessory lacrimal glands of Krause (fornices) and Wolfring (tarsus). Contains water, essential electrolytes ( Na + , K + , Cl − , HCO 3 − \text{Na}^+, \text{K}^+, \text{Cl}^-, \text{HCO}_3^- Na + , K + , Cl − , HCO 3 − ​ ), and antimicrobial/trophic proteins:

Lysozyme : Cleaves peptidoglycan cell walls of Gram-positive bacteria.

Lactoferrin : Chelates free iron, arresting bacterial replication.

Secretory IgA (sIgA) : Neutralises bacterial and viral adhesion.

Lipocalin : Chelates fatty acids and stabilises the lipid-water interface.

Epidermal Growth Factor (EGF) and Nerve Growth Factor (NGF) : Maintain epithelial and neurosensory homeostasis.

Mucin Component : Divided into soluble gel-forming mucins (predominantly MUC5AC synthesised by conjunctival goblet cells) that lubricate and clear debris, and membrane-associated mucins ( MUC1, MUC4, MUC16 ) expressed by the microvilli of corneal and conjunctival epithelial cells forming the glycocalyx , converting a naturally hydrophobic lipid-rich epithelial cell membrane into a hydrophilic wettable surface.

2. The Pathophysiological "Vicious Circle" of Dry Eye

The central mechanism driving all forms of DED is tear film hyperosmolarity , which triggers a self-perpetuating inflammatory cascade:

Initiating Stress : Evaporative excess (MGD) or aqueous deficiency leads to excessive water loss from the ocular surface.

Tear Hyperosmolarity : Evaporation concentrates electrolytes, driving tear osmolarity above physiological levels ( > 308 mOsm/L > 308\text{ mOsm/L} > 308 mOsm/L ). Hyperosmolarity imposes osmotic stress on corneal and conjunctival epithelial cells.

Pro-Inflammatory Signaling : Hyperosmolar stress activates mitogen-activated protein kinases (p38 MAPK, JNK) and the nuclear transcription factor NF- κ \kappa κ B within epithelial cells.

Inflammatory mediators and proteases : Stimulated cells release pro-inflammatory cytokines ( IL-1 β \beta β , TNF- α \alpha α , IL-6 ), chemokines, and matrix metalloproteinases ( MMP-9 ).

Goblet Cell Apoptosis & Epithelial Damage : Inflammatory mediators trigger apoptosis of conjunctival goblet cells (reducing MUC5AC) and disrupt epithelial tight junctions ( claudins, occludins ).

Tear Instability & Amplification : Loss of mucin and irregular epithelia further destabilise the tear film, accelerating evaporation and worsening hyperosmolarity.

Neurosensory Dysregulation : Chronic inflammation damages peripheral corneal nerve terminals, leading to either neuropathic pain (hyperalgesia/allodynia: severe symptoms with minimal signs) or neurotrophic hypoesthesia (blunted reflex tearing and blink rate).

3. Classify the Drivers

Aqueous deficiency and evaporation remain useful concepts but often overlap. TFOS DEWS III groups drivers involving tears, lids, ocular surface and systemic factors. Assess gland secretion, lipid/tear stability, blink and exposure, mucin/surface disease, medications, allergy and neuropathic symptoms. Sjögren disease can involve severe aqueous deficiency and needs systemic assessment. Do not assign a universal percentage of all dry-eye patients to one subtype. Symptoms without signs and signs without symptoms require careful differential assessment rather than automatic escalation of anti-inflammatory drops.

4. Symptoms and Homeostasis Testing

TFOS DEWS III uses compatible symptoms together with at least one marker of lost homeostasis after considering mimics. The abbreviated OSDI-6 symptom questionnaire uses a cutoff of at least 4. Perform less invasive tests before dye and contact tests alter the tear film.

Examples of diagnostic markers are non-invasive breakup time below 10 seconds, fluorescein breakup below 5 seconds, osmolarity at least 308 mOsm/L in the higher eye or an inter-eye difference above 8, and specified surface-staining patterns. Thresholds depend on protocol and do not independently define severity or the treatment needed. Record corneal, conjunctival and lid-margin staining separately. Schirmer testing and secretion/lid assessment help identify drivers; a positive MMP-9 test alone does not mandate treatment.

Seek alternative explanations such as allergy, infection, exposure, medication toxicity or neuropathic pain. Compare symptoms with function and explain uncertainty. See the TFOS DEWS III summaries .

5. Blepharitis & Meibomian Gland Dysfunction (MGD)

Blepharitis is an inflammatory condition of the eyelid margins, categorised anatomically into anterior and posterior disease.

Anterior Blepharitis

Involves the base of the eyelashes and lash follicles:

Staphylococcal Blepharitis : Chronic colonization by Staphylococcus aureus or S. epidermidis . Slit-lamp biomicroscopy reveals hard, brittle, fibrinous collarettes encasing the lash shafts, ulcerative lash margins, madarosis (loss of eyelashes), trichiasis, and poliosis (whitening of lashes).

Seborrhoeic Blepharitis : Strongly associated with seborrhoeic dermatitis. Features soft, greasy, oily scales along the eyelid margins and lashes without ulceration.

Demodex blepharitis: Collarettes at the lash bases support mite-associated disease. Assess symptoms and concurrent lid/surface problems. Treatment depends on the locally available, appropriately authorized product and its evidence. Tea-tree-derived products can irritate or injure the ocular surface; avoid concentrated home preparations and do not routinely place skin ivermectin cream in the eye. Clinician-directed lid care and selected anti-mite treatment require monitoring of tolerability.

Posterior Blepharitis & Meibomian Gland Dysfunction (MGD)

MGD is a chronic, diffuse abnormality of the meibomian glands characterised by terminal duct obstruction and qualitative/quantitative alterations in glandular lipid secretion.

Pathophysiology : Hyperkeratinisation of ductal epithelium → \rightarrow → thick, turbid meibum with elevated melting temperature ( > 35 ∘ C > 35^\circ\text{C} > 3 5 ∘ C ) → \rightarrow → ductal plugging → \rightarrow → cystic dilatation and eventual intraglandular atrophy.

Biomicroscopic Signs : Telangiectatic blood vessels crossing the mucocutaneous junction, plugging and pouting of meibomian orifices, thickened "toothpaste-like" meibum upon digital expression, irregular lid margin, and foamy tear meniscus (lipid saponification by bacterial lipases).

Non-Contact Infrared Meibography : Direct imaging of glandular silhouettes in the everted tarsus. Documents gland dropout, shortening, and tortuosity , quantified via the meiboscore (Grade 0: no dropout; Grade 1: < 33 % < 33\% < 33% loss; Grade 2: 33 – 66 % 33–66\% 33–66% loss; Grade 3: > 66 % > 66\% > 66% loss).

6. Management Matched to the Drivers of Disease

TFOS DEWS III (2025) updates the earlier report and emphasises treatment selected for tear deficiencies, eyelid abnormalities, ocular surface changes and systemic contributors. A patient often has several drivers. Review symptoms and functional priorities as well as objective findings; a single test does not mandate one drug.

Begin with education, appropriate tear supplementation and feasible environmental or blink changes. For meibomian dysfunction, use safe lid warming and hygiene, then select further treatment according to gland function, inflammation, tolerance and evidence. Avoid excessive heat or undiluted irritating cleansers. Persistent unilateral pain, photophobia or reduced vision requires evaluation for other pathology.

Clinical driver Treatment direction and monitoring

Aqueous deficiency Tear supplementation, consideration of conservation and assessment for relevant systemic disease

Meibomian/lid-margin disease Lid care, lipid supplementation and selected device or medical therapy

Surface inflammation Appropriate short-course steroid or longer-term immunomodulation with pressure and infection monitoring

  • Exposure or anatomical abnormality Improve closure and surface protection; selected lid or surface procedures
  • Epithelial failure or sensory loss Investigate neurotrophic disease and use specialist restorative treatment

Punctal occlusion is one option for tear conservation. Consider the degree of inflammation and treat it appropriately, but evidence does not establish that plugs invariably worsen inflammation unless all anti-inflammatory therapy precedes insertion. Explain extrusion, irritation, epiphora and infection risks and reassess the response.

Availability of ciclosporin formulations, lifitegrast, secretagogues and Demodex treatments differs by country and authorisation. Lotilaner has a US indication for Demodex blepharitis; do not infer EU access from that approval. Tea-tree formulations may irritate or damage the surface and should not be treated as a harmless universal first-line remedy. Selected systemic antibiotics for rosacea/MGD require assessment of contraindications and an appropriate protocol.

Nutritional supplementation is not a guaranteed dry-eye treatment. The DREAM trial did not find a significant advantage of the tested omega-3 supplement over its comparator. Correct a demonstrated deficiency when indicated and distinguish uncertain adjuncts from established treatment for severe ocular disease.

Measure outcomes meaningful to the patient, such as reading fluctuation and comfort, and recheck the relevant surface signs. Persistent symptoms with minimal signs may require assessment of neuropathic pain, while marked staining with little pain raises concern for reduced sensation. Severe epithelial disease may require serum drops, amnion or protective surgery under specialist care.

Source: TFOS DEWS III reports and summaries .

DEWS III recommends symptom screening with OSDI-6 , whose six items refer to the preceding month; a summed score of at least 4 is the symptom cutoff. Confirm loss of homeostasis using tear stability or osmolarity and comprehensive surface staining, starting with the least invasive tests. Non-invasive breakup time below 10 seconds and fluorescein breakup time below 5 seconds are different measures and are not interchangeable. An isolated MMP-9 result does not itself select or mandate anti-inflammatory treatment.

Loading diagram... TFOS DEWS II Diagnostic and Staging Flowchart